Condition: Rectal Cancer · Synchronous Liver Metastases · Antineoplastic Combined Chemotherapy Protocols · Sponsor: Assistance Publique - Hôpitaux de Paris
SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.
This description comes directly from the study's public registry record.
Stéphane BENOIST, MD PhD · +33 (0)1 45 21 34 72 · stephane.benoist@aphp.fr
Solafah ABDALLA, MD PhD · +33 (0)1 45 21 34 70 · solafah.abdalla@aphp.fr
Always discuss trial participation with your own doctor first.
| Digestive Surgery Department, Bicêtre University Hospital AP-HP | Le Kremlin-Bicêtre, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07467434